SCCA-IgM predicts survival in HCC patients
As reported in the Journal of Gastroenterology & Hepatology, SCCA-IgM levels are elevated in patients with hepatocellular carcinoma (HCC) compared to patients with cirrhosis and healthy controls. Not only does the SCCA-IgM level predict overall and progression-free survival in HCC patients, but the sensitivity of SCCA-IgM in patients with HCC was 2-fold greater than AFP. A decline in SCCA-IgM levels was shown to be associated with response to treatment.
Elevated ?-GT predicts HCC in hepatitis C patients with sustained response
As reported in the Journal of Hepatology, an elevated baseline ɣ-GT level is the strongest predictor of developing HCC in non-cirrhotic patients with hepatitis C and a sustained virologic response (HR = 6.44), followed by age (HR = 3.68).
Calcium reduces CRC risk
As reported in the International Journal of Cancer, there is an 8% reduction in CRC risk with each 300 mg/d increase in calcium intake based on 15 studies involving 12305 patients who took 250-1900 mg of calcium/day over a 3.3-16 year follow-up period. The beneficial effect extended beyond 1000 mg/d.